Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Ratliff
Brooke
B
Dietze
Eric C
EC
Bean
Gregory R
GR
Moore
Cassandra
C
Wanko
Sam
S
Seewaldt
Victoria L
VL
D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D017374:Paroxetine / Q000008:administration & dosage* / Q000494:pharmacology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D013629:Tamoxifen / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood* / Q000493:pharmacokinetics
D018687:Antidepressive Agents, Second-Generation; D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D013629:Tamoxifen; C016601:afimoxifene; C028787:N-desmethyltamoxifen